The Birth of Sativex: How GW Pharmaceuticals Developed Cannabis Medicine
GW Pharmaceuticals developed multiple cannabis-based prescription medicines including Sativex (THC:CBD), completing phase III trials showing significant pain reduction in MS and other neuropathic conditions.
Quick Facts
What This Study Found
GW Pharmaceuticals was developing distinct cannabis-based prescription medicines using three delivery systems: sublingual spray, sublingual tablet, and inhaled (non-smoked) forms. Four formulations were being tested: High THC, THC:CBD (narrow ratio), THC:CBD (broad ratio), and High CBD.
Completed phase III trials demonstrated that THC:CBD (narrow ratio) produced statistically significant reductions in neuropathic pain in MS patients and other conditions, with improvements in additional MS symptoms observed. Phase II trials across MS, spinal cord injury, neuropathic pain, peripheral neuropathy, rheumatoid arthritis, and perioperative pain all provided positive results with excellent safety profiles. Bayer AG was licensed for UK commercialization under the Sativex brand name.
Key Numbers
Five phase III trials underway. One trial included more than 100 patients with cancer pain. Phase II trials completed across 6 therapeutic areas. UK commercialization licensed to Bayer AG. IND approval for US phase II trials received.
How They Did This
This was a pharmaceutical industry review documenting the development program for GW Pharmaceuticals' cannabis-based medicines, including summaries of completed and ongoing clinical trials across multiple indications.
Why This Research Matters
This review documented a watershed moment in cannabinoid medicine: the first pharmaceutical company successfully developing standardized cannabis-based prescription drugs through the conventional regulatory pathway. The development of Sativex demonstrated that cannabis could meet pharmaceutical standards for quality, safety, and efficacy.
The Bigger Picture
Sativex was eventually approved in multiple countries for MS spasticity, becoming the first cannabis-based pharmaceutical to achieve broad regulatory approval. GW Pharmaceuticals later developed Epidiolex (CBD) for epilepsy. The company was acquired by Jazz Pharmaceuticals in 2021 for $7.2 billion, validating the commercial potential of cannabis-based medicines.
What This Study Doesn't Tell Us
This was an industry-produced review that presented the company's development program in favorable terms. Detailed trial data and methodology were not provided. The review was written before most trial results were published in peer-reviewed form.
Questions This Raises
- ?How did the actual market launch timeline compare to the projected 2003 date?
- ?Did the security monitoring technology to prevent abuse ever prove necessary or effective?
Trust & Context
- Key Stat:
- Phase III trials showed significant neuropathic pain reduction; Bayer licensed Sativex
- Evidence Grade:
- This is a pharmaceutical development review summarizing multiple clinical trials, providing moderate-level evidence through aggregated trial results.
- Study Age:
- Published in 2003. Sativex was subsequently approved in 25+ countries, and GW was acquired by Jazz Pharmaceuticals in 2021.
- Original Title:
- Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
- Published In:
- Drugs in R&D, 4(5), 306-9 (2003)
- Authors:
- Database ID:
- RTHC-00132
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is Sativex?
Sativex (nabiximols) is a mouth spray containing THC and CBD extracted from cannabis plants. Developed by GW Pharmaceuticals, it was the first cannabis-based prescription medicine to achieve broad regulatory approval, primarily for MS spasticity.
Is Sativex available in the US?
As of this review, GW was seeking US regulatory pathway. Sativex has faced a complex regulatory path in the US and has been approved in many other countries but not the US, where the company's CBD product Epidiolex achieved approval instead.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- full-spectrum-vs-broad-spectrum-vs-isolate
- thc-patches-suppositories-topicals-explained
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00132APA
. (2003). Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.. Drugs in R&D, 4(5), 306-9.
MLA
. "Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.." Drugs in R&D, 2003.
RethinkTHC
RethinkTHC Research Database. "Cannabis-based medicines--GW pharmaceuticals: high CBD, high..." RTHC-00132. Retrieved from https://rethinkthc.com/research/unknown-2003-cannabisbased-medicinesgw-pharmaceuticals-high
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.